



Date: 14th November, 2024

BSE Limited

Dept. of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 BSE Scrip Code - 541304

National Stock Exchange of India Limited

Dept. of Corporate Compliances, Exchange Plaza, C-1 Block-G, Bandra Kurla Complex, Bandra (E) Mumbai- 400 051

NSE Symbol: INDOUS

Sub: Outcome of Board Meeting held on Thursday, November 14, 2024, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: Indo Us Bio Tech Limited

Dear Sir.

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Thursday, November 14, 2024 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

- The Board approved unaudited financial results of the company for the quarter/half year ended 30th September, 2024 along with limited review reports obtained from the Auditor of the Company.
- 2. Increase Authorised capital from Rs. 21,00,00,000 (Rupees Twenty-One Crore only) divided into 21,00,00,00 (Two crores ten lakhs Equity Shares of Re. 10/- (Rupee Ten) each to Rs. 31,00,00,000 (Rupees Thirty-One Crore only) divided into 31,00,00,00 (Three cores ten lakhs Equity Shares of Re. 10/- (Rupee Ten) each" and the consequent amendment to Memorandum of Association of the Company.
- 3. Approved Notice of Postal Ballot

 The copy of Notice of Postal Ballot will be submitted to exchange as soon as the same be dispatched to the Shareholders of the Company through email.
- 4. Appoint M/s. Amrish Gandhi & Associates, Practising Company Secretary scrutinizer to scrutinize the e-voting process for conducting the postal ballot through remote e-voting process in a fair and transparent manner.

The Board Meeting commenced at 11:30 A.M. and concluded at 12:15 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY DIVYANGBHAI DIVYANGBHAI JOSHI
JOSHI Date: 2024.11.14 12:20:30

Ms. Dimpy Joshi

Company Secretary & Compliance officer





Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex, Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

LIMITED REVIEW REPORT

To, The Board of Directors, Indo US Bio-Tech Limited, Ahmedabad

We have reviewed the accompanying statement of unaudited financial results of **Indo US Bio-Tech Limited** for the half year ended 30th September 2024. This statement which is the responsibility of the Company's Management and has been approved by Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates

Chartered Accountants

FRN: 103117W

Gautam Nandawat

Partner, M No: 032742

UDIN: 24032742BKCSBQ2239

Place: Chhatrapati Sambhajinagar

Date: 14th November 2024





Indo US Bio-Tech Limited CIN: L01122GJ2004PLC043550

Regd Office: 309, Shanti Mall, Satadhar Char Rasta Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, India, 380061

Statement of standalone unaudited financial results for the quarter ended on 30th September 2024

	PARTICULARS			(Amount in Lakhs			
		30-09-2024 (Unaudited)	Quarter Ended 30-06-2024	30-09-2023	Half year 30-09-2024	ended 30-09-2023	Year ended 31-03-2024
1	Income	(communical)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Revenue from operations	224724					(Hanney)
	Other income	2,217.26	2,471,77	1,581.37	4,689,03	3.495.63	7,283.6
	Total income from operations	1.52	2.80	0.31	4.33	3.16	
н	Expenses	2,218,79	2,474.57	1,581.68	4,693.36	3,498.80	31.9
	Purchases					3,170,00	7,315.5
	Production Expenses	9.37	13.39	354.09	22.77	461.70	Mark 4
	Change in Inventocies	1,113.67	1,262.35	1,216.76	2,376,02	1,991.86	588.2
	Employee benefit expenses	329,53	529.93	(577.95)	859.46		6,896.0
	Finance costs	24.23	28.82	35.65	53.06	(27.29)	(2,547.1
		51.56	32,99	40.92	84.55	67.42	117.0
	Depreciation and amortization expenses	17.53	20.01	21.32	VVII. 227779.78	78.12	151.0
	Other expenses	220.31	268.25	293.51	37.55	41.37	80.03
	Total expenses	1,774.21	2,155,75		496.56	443.49	1,149.98
	Profit/(Loss) before exceptional items and	MILLS SOFTER IN	4,133,73	1,384.29	3,929.96	3,056.67	6,435.15
111	tax	444,58	318.82	197.39			
iv	Exceptional items- Prior Period Items	College Colleg			763.39	442.12	880.44
V	Profit/(Loss) before tax	444.50					400.41
¥T:	Tax expenses	444.58	318.82	197.39	763.39	442.12	880,44
	a) Current tax					110112	000,44
	b) Income tax prior year	0.59	0.79	9.38	1.37	21.00	
	b) Deferred tax	(1.68)		25.38	(1.68)		36.94
	Total tax expenses	9.72	1.18	(4.28)	10.90	25,38	25.77
1714	Not Drofts // Land C. of	6.63	1,96	30.47	10.59	(8.50)	(7.41
-43	Net Profit/(Loss) for the period/year	435.95	316.86	166.92		37.88	55.30
m	Other comprehensive income (net of tax)			100.72	752.81	404.24	825.14
	hems that will not be reclassified to profit						
	or loss:						
		16 22		1000			
	f) Remeasurement of post employment		ATTENDED BY	30.00		*	Contract of the
	benefit obligations	2.28					
	ii) Income-tax relating to items that will not				2.28		
	be reclassified to profit or loss	49.5					
	Total other comprehensive income	2.28		1000			
	Total comprehensive income for the	2.20			2.28		
X.	period/year (VII+VIII)						
	Paid-up equity share capital (face value of	433.67	316.86	166.92	750.53	404.24	
	Rs.10 per share)					404.64	825.14
1	Other equity (excluding revaluation reserve)	2,005.20	2,005.20	2,005.20	2,005.20	2,005.20	
11	EPS in Rs. (Face Value of Rs. 10/- each)*					2,005.26	2,005.20
9	Basic						4,269.52
1	-Diluted	2,16	1.58	0.83	200		
	not annualised	2.16	1.58	0.83	3.74	2.02	4.11
	unt auturansed			0.03	3.74	2.02	4.11

[1] The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th November 2024 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation, processing and trading.

(3) The company has issued bonus share in the ratio of 1:1 as on 01st September, 2023.

(4) The figures have been regrouped/rearranged wherever necessary

(4) Investor complained - opening unresolved -NIL Received during the quarter NIL resolved during the quarter-NIL and balance unresolved at the end of the quarter

Place Ahmedabad Date 14.11.2024

For, INDO US BIO-TECH LUTTED

Gantaris -

DIRECTOR



UDIN: -24032742BKCSBQ2239

Regd. Office:

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061 @ 079-27491807 @ +91-9909043999





Indo US Bio-Tech Limited CIN: L01122GJ2004PLC043550

Disclosure of Standalone Assets and Liabilities (Balance Sheet) as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2024

Standalone Assets and Liabilities (Balance Sheet) as at 30th September, 2024

	30-09-2024 Amount in Lakhs	31-03-2024 Amount in Lakhs
ASSETS	Unaudited	Audited
I) Non-current assets		
(a) Property, Plant & Equipements (b) Capital work-in-progress (c) Deferred tax assets (Net) (d) Other Non-current Assets II) Current assets (a) Inventories (b) Financial Assets	643.47 424.97 54.98 18.64 1,142.06	669.1: 377.8: 65.88 23.64 1,136.4 9
(i) Trade receivables (ii) Cash and cash equivalents (iii) Loans and Advances (c) Current Tax Assets (Net) (d) Other Current Assets	2,368.87 104.15 878.39	1,904.50 109.84 117.85
Total	7,642.04	3.41
EQUITY AND LIABILITIES Equity	8,784.10	7,309.13 8,445.63
(a) Equity Share Capital (b) Other Equity	2,005.20 5,020.04 7,025.24	2,005.20 4,269.52 6,274.72







Regd. Office:

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061 © 079-27491807 ©+91-9909043999



(AN ISO CERTIFIED COMPANY)

CIN LO1122GJ2004PLC043550

Liabilities

- I) Non-Current Liabilities
 - (a) Financial Liabilities (i) Borrowings
 - (b) Provisions
 - (c) Deferred Tax Liabilites (Net)
 - (d) Other non-current liabilities

II) Current Liabilities

- (a) Financial Liabilities
 - (i) Borrowings
 - (ii) Trade Payables
 - MSME
 - Other than MSME.
- (b) Other Current Liabilities
- (c) Provisons
- (d) Current Tax Liabilites (Net)

me.						

	4.4.
	*
324.72	280.20
6.73	4.45
95.84	139.86
427.29	424.52

1,188.56	1,152.22
20.57	5.05
44.40	433.72
76.56	120.09
0.10	0.10
1.37	35.21
1,331.56	1,746.39
8,784.10	8,445.63

Note: Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

Date: 14.11.2024 Place: Ahmedabad



For and on behalf of Board of Directors

For, INDO US BIO-TECH LIMILE

Jagdish D Ajudiya Managing Director DIN: 01745951

DIRECTOR

N. ASS CCOUNTANT

FOR GAUTAM N ASSOCIATES CHARTERED ACCOUNTANTS

GAUTAM NANDAWAT

(Partner) UDIN: 24032742BKCSBU2239



Regd. Office:

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061 ⊕ 079-27491807 ⊕+91-9909043999



INDO US

(AN ISO CERTIFIED COMPANY) CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited

Disclosure of Standalone Cash Flow Statement as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2024

Standalone Statement of Cash Flow for the Half Year ended on 30th September 2024

		2024-09-30 Amount in Lakhs	2024-03-31 Amount in Lakhs
		Unadited	Audited
Cash flow from operating activities:			
Net profit before tax as per statement of profit and loss			
Adjusted for:		761.11	880.44
Provision /(Reversal) for trade receivable			
Provision /(Reversal) for advances		2.99	(6.00)
Provision /(Reversal) for gratuity			0.47
Discard of assets		2,28	(0.10)
Depreciation & amortization			0.43
Interest Income		37.55	80.05
Interest & finance costs		(0.93)	(1.22)
Operating cash flow before working capital changes		84.55	151.00
Adjusted for:		887.54	1,105.06
(Increase)/ decrease in inventories			
(Increase)/ decrease in trade receivables		884.32	(2,482.19)
(Increase)/ decrease in other current assets		(467.35)	575.72
(Increase)/ decrease in other non current assets		1.97	(1.79)
Increase/ (decrease) in other non current liabilities		5,00	(0.01)
Increase/ (decrease) in trade payables		(44.02)	46.96
- Increase/ (decrease) in provisions		(373.80)	299.13
Increase/ (decrease) in other current liabilities			
Cash generated from / (used in) operations		(43.53)	29.97
Income taxes paid		850.14	(427.14)
Net cash generated from/ (used in) operating activities		(33.52)	(31.05)
	[A]	816.61	(458.20)
Cash flow from investing activities:			
Purchase of fixed assets and capital advance pald			
Subsidy Received against Fixed Assets		(59.01)	(261.01)
Increase/ decrease in short term loans and advances			7.04
Interest income		(760.53)	680.33
Net cash flow from/(used) in investing activities	-	0.93	1.22
	[B]	(818.61)	427.58







Regd. Office:



(AN ISO CERTIFIED COMPANY) CIN LO1122GJ2004PLC043550



Cash flow from financing activities:

Proceeds from long term borrowing (net) Proceeds from short term borrowing (net) Interest & finance costs

Net cash flow from/(used in) financing activities

Net increase/(decrease) in cash & cash equivalents Cash & cash equivalents as at beginning of the year Cash & cash equivalents as at end of the year

44.52	109.73
36.34	162.78
(84.55)	(151.00)
(3.69)	121.51
(5.69)	90.89
109.84	18.95
104.15	109.84
	36.34 (84.55) (3.69) (5.69) 109.84

Date: 14.11.2024 Place: Ahmedahad



For, INDO US BIO-TECHALIMITED

For and on behalf of Board of And

Jagdish D Ajudiya **Managing Director** DIN: 01745951

IA+B

DIRECTOR

FOR GAUTAM N ASSOCIATES

GAUTAM NANDAWAT

(Partner)

UDIN: 24032742BKC5BQ2239



Regd. Office:

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061 **⊙**079-27491807 **⊙**+91-9909043999